Abstract Mutations in the p53 gene are among the most frequent genetic events in human cancer and may be triggered by environmental and occupational exposures. We examined the association of clinical and pathological characteristics of breast tumors and breast cancer risk factors according to the prevalence and type of p53 mutations. Using tumor blocks from incident cases from a case-control study in western New York, we screened for p53 mutations in exons 2-11 using the Affymetrix p53 Gene Chip array and analyzed case-case comparisons using logistic regression. The p53 mutation frequency among cases was 28.1 %; 95 % were point mutations (13 % of which were silent) and the remainder were single base pair deletions. Sixty seven percent of all point mutations were transitions; 24 % of them are G:C[A:T at CpG sites. Positive p53 mutation status was associated with poorer differentiation (OR, 95 % CI 2.29, 1.21-4.32), higher nuclear grade (OR, 95 % CI 1.99, 1.22-3.25), and increased Ki-67 status (OR, 95 % CI 1.81, 1.10-2.98). Cases with P53 mutations were more likely to have a combined ER-positive and PR-negative status (OR, 95 % CI 1.65, 1.01-2.71), and a combined ER-negative and PRnegative status (OR, 95 % CI 2.18,). Body mass index [30 kg/m 2 , waist circumference [79 cm, and waistto-hip ratio [0.86 were also associated with p53 status; obese breast cancer cases are more likely to have p53 mutations (OR, 95 % CI 1.78, 1.19-2.68). We confirmed that p53 mutations are associated with less favorable tumor characteristics and identified an association of p53 mutation status and adiposity.
Introduction
p53 is a multifunctional tumor suppressor gene that plays a central role in deciding cellular fate after DNA damage by arresting cell cycle and allowing DNA repair or inducing apoptosis [1] [2] [3] . In sporadic breast cancers, p53 is mutated in about 25 % of all tumors [4] . Mutation frequencies are higher than 80 % in the basal-like breast cancer subtype [5, 6] and range from 43 to 62 % in triple-negative breast cancer [7] .
P53 mutations are a hallmark of many cancers, and the majority of them are point missense mutations in the coding region [8] [9] [10] [11] . More than 90 % of p53 mutations are clustered in exons 4-10 and correspond to the DNA binding domain of the p53 protein [4] . The spectrum and distribution of p53 mutations in sporadic breast cancer are similar to other cancers, especially lung cancer, with respect to the substantial rate of G:C to T:A transversions, and similar to colon cancer with respect to the increased rate of G:C to A:T transitions, deletions, and insertions [8, 9, 12] .
Several studies have measured nuclear staining of p53 as a proxy for p53 gene alterations in breast cancer, and reported associations with poor outcomes and worse pathological characteristics, such as hormone receptor negative, HER2 positive, high grade, and high proliferative tumors [8] . However, as DNA sequencing is the gold standard for detecting mutations, other studies have performed mutation screening followed by direct sequencing of p53 exons 2-11 [8] . More recent work involves nextgeneration sequencing for detection of p53 mutations [13] . In general, p53 mutations are independent predictive factors of poor prognosis for breast cancer survival; however, more recent studies indicate that certain specific p53 mutations located in the DNA binding domain are associated with even lower survival rates [14] [15] [16] [17] . Therefore, the full spectrum of p53 mutation needs to be studied more specifically with regard to clinical characteristics and outcomes.
Although there is clear evidence that p53 mutations are critical to breast carcinogenesis, little is known about the determinants and time course of these mutations. Several studies have described the presence of p53 mutations in ductal carcinoma in situ lesions, suggesting that these mutations are an early event in the carcinogenic process [18] [19] [20] . Specific patterns of p53 mutations have been linked to certain exposures in several other cancer types providing etiological clues, including aflatoxin exposure for liver cancer, smoking for lung cancer, and sun exposure for skin cancer [9, [21] [22] [23] [24] . There are several studies which have investigated the relationship between p53 mutations and exposures in breast cancer likely to be important earlier in the carcinogenic process, although there are no consistent findings from these reports [25] [26] [27] [28] [29] .
In the present study, we characterized the prevalence and spectrum of p53 mutations in a large sample of breast cancer tumors to study the association of p53 mutations and markers of tumor aggressiveness, and breast cancer risk factors to determine if any particular exposures are differentially associated with particular p53 mutations.
Materials and methods

Study population
All subjects were part of the Western New York Exposures and Breast Cancer (WEB) study, a population-based casecontrol study of breast cancer conducted between 1996 and 2001, described in detail elsewhere [30] . Analyses presented here were restricted to cases from that study. Briefly, cases were residents of Erie and Niagara Counties, 35-79 years old, with pathologically confirmed primary, incident breast cancer and no history of cancer other than non-melanoma skin cancer.
Data on demographics, breast cancer risk factors, and anthropometric measures were obtained through extensive in-person interviews and self-administered questionnaires at the time of study participation; for cases, this was after diagnosis. Medical data, including clinical and pathological information on tumors, were abstracted from medical records using a standard protocol. We obtained archived tissue blocks for 920 cancer cases in the WEB study, and only tissue blocks with tumor tissue in them were analyzed (n = 734). A senior pathologist from Georgetown University confirmed the pathological diagnosis of breast cancer based on the tumors. All subjects provided informed consent, and the study was approved by the Institutional Review Boards of the University at Buffalo, Georgetown University and all participating hospitals.
Hormone receptor status
Estrogen receptor status, progesterone receptor status, and Ki-67 and HER2 status were determined by immunohistochemistry using standard protocols as previously described [31] . Briefly, 5-lm tissue slides were stained using a DAKO Autostainer (DAKO, Carpentaria, CA) and the DakoCytomationEnVision? system-HRP (DAB) kit. The Allred score for staining intensity and distribution of positive stained tumor cells was used to determine ER and PR status. A score cutoff value of 3 was chosen to establish hormone receptor status, with a score of 3 or more being considered positive. For Ki-67, in accordance with the majority of studies using Ki-67 as a categorical variable in breast cancer, we used a cutoff of 20 % positive stained cells [32] . HER2 protein expression was scored in a similar manner as the clinically used HercepTest TM . Tumors with a score of 0-2 were classified as HER2-negative, and tumors with a score of 3 were classified as HER2-positive. All stained slides were interpreted by a board certified pathologist.
p53 mutation detection
Mutations were detected by the Affymetrix p53 Gene Chip System (Affymetrix, Santa Clara, CA) to screen for mutations in the p53 gene as previously described [33] . Briefly, micro-dissection of the tumor tissue from a 20-lmthick slide was performed with a fine needle under the microscope, using an adjacent H&E stained slide for guidance to minimize the inclusion of normal cells. The dissected tissue was then subjected to DNA isolation using a phenol/chloroform/isoamyl alcohol extraction protocol. A multiplex PCR was carried out to amplify exons 2-11 of the p53 gene, and the product was fragmented, labeled, hybridized on the microarray, and scanned according to the manufacturer's instructions. A commercially available wild-type DNA was used as control. All positive mutation readings were subsequently confirmed by bidirectional sequencing using the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and the Mega BACE 1000 DNA Analysis capillary electrophoresis system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) according to the manufacturers' instructions.
Statistical analysis
We examined differences in demographics, breast cancer risk factors, and tumor characteristics according to p53 mutation status (present/absent) using t tests and Chisquare tests as appropriate and summarized the frequencies of p53 mutation types. We used unconditional logistic regression models to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) in case-case analyses to study the association of various tumor characteristics, including clinical state, histologic and nuclear grade, tumor size, lymph node involvement, combined ER/PR status, Ki-67 status, and HER2 status with p53 mutation status. We also evaluated the association of p53 status with smoking status, drinking status, and several measures of adiposity including body mass index (BMI), waist circumference, and waist-to-hip ratio, in strata defined by menopausal status. All models were adjusted for age at diagnosis, education, and race. When analyzing BMI, we used cutoffs of 25 and 30 kg/m 2 . We utilized clinically meaningful cutoffs for waist circumference and waist-to-hip ratio to present results by category. Statistical analyses were conducted using SAS Version 9.1 (SAS Institute, Cary, NC).
Results
We obtained tumor bocks from 920 (79 %) of the 1170 cases enrolled in our study; however, only 865 (94 %) had sufficient tumor tissue on slides and were subjected to p53 mutation analysis. Women for whom we obtained breast tumor tissue were slightly younger at diagnosis and had higher TNM stage disease, compared to women who either did not have blocks or insufficient tissue for analysis, but were similar in terms of tumor size, histologic and nuclear grade, and ER and PR status [34] . We obtained valid results for 734 subjects, with the remainder failing during the analytical process due to insufficient or poor DNA quality. There were few differences between women with and without p53 mutation status in our study; women with p53 status were approximately 2 years younger, more likely to have metastatic disease, lymph node involvement, higher nuclear grade, and higher TNM stage. There were no differences in tumor size, histologic grade, ER status, PR status, HER2 status, or Ki-67 between women with measurable versus not measurable p53 mutation status.
Characteristics of breast cancer cases according to p53 mutation status are shown in Table 1 . In bivariate comparisons, there were no differences for most risk factors between those with and without p53 mutations in their tumors. Breast cancer cases with p53 positive tumors had a statistically significant larger BMI (28.5 vs 28.0 kg/m 2 for p53 negative tumors, p \ 0.01). With regard to tumor characteristics, p53 mutation positive cases had a higher proportion of poorly differentiated tumors (65 vs 46 %; p \ 0.01), and a distribution weighed toward higher nuclear grade (p \ 0.01). Cases who have p53 positive tumors were also more likely to have ER-negative and PRnegative tumors, and more likely to be Ki-67 positive (all p \ 0.02). We examined differences with regard to molecular subtype, which represents a subgroup of our larger set. Here we observed that 26 % of p53 positive tumors were triple negative versus 15 % of p53 negative tumors, p \ 0.01.
Distributions of cases across the different types of p53 mutations and effect on DNA sequence are detailed in Table 2 . The p53 mutation frequency among cases was 28 %, of which 95 % were point mutations (13 % of them silent) and the remainder were single base pair deletions. Transitions represented 67 % of all point mutations, with 36.5 % of transitions being G:C[A:T at CpG sites. Similar to the IARC database [4] , most mutations were localized in exons 5 (35 %), 6 (16 %), 7 (23 %), and 8 (20 %), with hotspots in codons 303, 338, and 350 (data not shown).
Descriptive statistics according to mutation type and mutation effect are detailed in Supplementary Table 1 . Women with transition mutations had a slightly higher BMI than women whose tumors are p53 negative (29.4 vs 28.0 kg/m 2 ; p = 0.02), as well as a higher frequency of poorly differentiated (67 vs 46 % for p53-negative; p = 0.001) and high nuclear grade tumors (60 vs 38 % for p53-negative; p \ 0.001). Also, tumors for women with transition mutations in p53 were more frequently ER and PR negative, and more frequently of the triple-negative subtype (27 vs 15 % in p53 negative cases; p = 0.01). Notable differences for transversion-type mutations include a higher frequency in non-white cases (16 vs 8 % in p53 negative cases; p = 0.04), poor nuclear grade (59 vs 38 % in p53 negative cases; p = 0.01), higher frequency of PR-negative tumors (50 vs 32 % in p53 negative cases; p = 0.01), and more staining for Ki-67 compared to breast cancer cases with no p53 mutation (18 vs 9 % in p53 negative cases; p = 0.04).
We observed several statistically significant differences in groups of cases according to p53 mutation effect. Women with missense mutations had a higher BMI (29.4 vs 28.0 kg/m 2 ; p = 0.02), larger tumors (2.1 vs 1.8 cm; a Number of subjects with available data p = 0.03), poor histologic and nuclear grade (both p values \0.001), higher frequency of ER-and PR-negative tumors as well as more triple-negative tumors (27 vs 15 % in p53 negative cases; p = 0.002), and higher Ki-67 index compared to women with no p53 mutation (16 vs 9 %; p = 0.03). Other types of p53 mutations classified by type had small sample size; therefore, we are unable to draw robust conclusions for other p53 effects (frameshift, nonsense, silent and splice). The associations of p53 mutations (yes/no) and of mutation type (transitions and transversions) with several tumor characteristics and various measures of adiposity are shown in Table 3 . We observed that cases with poorly differentiated tumors and those with a higher nuclear grade are more likely to have p53 mutation positive tumors; OR, 95 % CI 2.29, 1.21-4.32 and 1.99, 95 % CI 1.22-3.25, respectively. These results were similar when we stratified these analyses according to mutation type (transitions and transversions); however, the estimates did not reach statistical significance for transversions. Tumors that were ER and PR negative were more likely to be p53 positive. Similarly, the luminal A type was inversely associated with p53 OR, 95 % CI 0.44, 0.28-0.68. Ki67 was also associated with having a p53 mutation, OR, 95 % CI 1.81, 1.10-2.99.
We observed no difference in the associations of ER and PR status with p53 mutations by menopausal status. ERand PR-negative cases were more likely to have a p53 positive tumor (OR, 95 % CI 2.17, 1.09-4.30 and 2.14, 95 % CI 1.31-3.50 for pre-and postmenopausal women, respectively) (data not shown).
All three measures of adiposity were examined (BMI, waist circumference, and waist-to-hip ratio) and all three were associated with having a p53 positive tumor; ORs ranged from 1. We observed no statistically significant associations of p53 mutation status with the following breast cancer risk factors: age at first birth, age at menarche, number of births, family history, or previous benign breast disease (Supplementary Table 2 ); nor did we observe differences by menopausal status (data not shown).
Discussion
In this study, the spectrum and distribution of p53 mutations were investigated in breast cancer cases from a large population-based case control study. P53 mutations were identified in 25.6 % of tumors, similar to other reports for breast cancer and the IARC p53 mutation database [4] . We confirm that women with p53 mutations in their breast tumors were more likely to have poorly differentiated, high grade, hormone receptor negative, and highly proliferative tumors, especially in postmenopausal cases. Moreover, postmenopausal, but not premenopausal, breast cancer cases with high adiposity measures were more likely to have p53 positive breast tumors. Our work may suggest a role of p53 in mechanisms associated with adiposity and cancer, including inflammation and insulin resistance.
Our findings are in agreement with others, as p53 mutations have been associated with larger tumor size and higher grade, positive nodal status, and negative ER and PR status [17, 35] . In spite of the fact that most studies have relied on measurement of p53 expression rather than the more direct measurement of p53 mutations, there is a consistent finding of an association of p53 mutations with poor prognosis and breast cancer mortality [17, 36] . When we stratified the subjects by menopausal status, the associations of tumor characteristics that are related to poor prognosis and p53 status were present in both pre-and post-menopausal women; however, they were only statistically significant in post-menopausal cases. The lack of significance in pre-menopausal women may be due to the limited sample size in that group; our study is unable to rule out the possibility of no association in pre-menopausal women. Among a number of breast cancer risk factors examined herein for associations with p53 mutations, we identified an association of higher adiposity values (larger BMI, waist circumference and waist-to-hip ratio) with p53 mutations in postmenopausal women. We observed an approximate twofold increased odds of having a p53 mutation for women in the higher categories of adiposity. It is well established that BMI is associated with increased risk of breast cancer among postmenopausal women [37] ; in studies of premenopausal women, BMI is either not associated with risk or is negatively associated with risk [38] . A Dutch study reported no significant trends in risk for increasing BMI according to p53 status measured using immunohistochemistry [39] . While our findings need to be replicated, there is mounting evidence for p53 involvement in inflammation and insulin resistance [40] .
There is evidence that genes associated with obesity are regulators of p53 [41, 42] . One of these genes is SIRT1, which can bind and deacetylate p53, preventing cell senescence and apoptosis following DNA damage [41] . Another negative regulator of p53 is MDM2; the Mdm2-p53 pathway and the PI3K/Akt pathways are involved in stress response and important in cellular homeostasis, controlling proliferation, senescence, and apoptosis [43] [44] [45] .
Animal models have demonstrated that excess caloric intake can lead to oxidative stress in adipose tissue and ?/-) that were subjected to diet-induced obesity had reduced p53 expression signaling and downstream expression of p21 [46] . Other evidence comes from breast cancer cell lines where the proliferative effects of leptin may down-regulate p53 [47] . Collectively, this evidence suggests that obesity may influence p53 expression via inflammatory processes.
There are few studies of the association of p53 and adiposity in other cancers. Figueroa et al. studied different types of esophageal and gastric adenocarcinoma, and although the groups of cases were fairly small, they reported that the association of BMI and esophageal adenocarcinoma (n = 122) showed higher odds of disease in P53 positive cases compared to P53 negative cases [48] . [50] . These results differ from our findings; we did not find an association with transversion-type mutations and breast cancer. Finally, in a study of 75 patients with bladder cancer, overweight patients had the lowest frequency of p53 mutations; obesity was not positively related to p53 status for tumors at that site [51] . While the epidemiologic evidence is limited, studies on obesityrelated cancers show some evidence of a link between adiposity and p53 mutations that deserves further attention.
In three previous studies, cigarette smoking was associated with the prevalence and spectrum of p53 mutations in breast cancers, measured both by immunohistochemistry and direct sequencing [35, 52] . However, this was not observed in this study. In one of these studies, a higher proportion of G:C?T:A transversions in postmenopausal breast cancer cases who are smokers also was reported [35] . In our study, 39 % of smokers had this particular mutation (7 of 18 with the mutation), but it was not statistically increased, perhaps due to small study size.
P53 genetic alterations are usually associated with accumulation and detection of p53 expression by IHC in tumors, the reason for using IHC as a proxy for p53 mutations. Mutant p53 also inactivates wild-type p53 for a dominant negative effect, and depending on the mutation type, in addition to leading to the expression of an inactive protein, it can also have a proto-oncogenic effect through a gain-of-function mechanism [53] . Herein we did not measure p53 expression, so we cannot infer the relationship between mutations and expression in our study. Moreover, due to low numbers in strata, when we stratified according to mutation effect, we observed that especially missense mutations were associated with higher BMI and tumors with poor prognostic characteristics, probably due to the fact that these mutation types represented the great majority in our study. However, a recent study reported that breast cancer patients with nonsense mutations have the poorest prognosis in comparison with wild-type cases and other types of mutations [54] . We also found in our study that nonsense mutations were associated with grade, stage, ER/PR status, and molecular subtype when compared to wild-type p53 tumors; however, these associations were also present for missense mutations.
When stratified according to mutation type, transversions were more frequent in non-white patients. There are some reports of different distribution and pattern of p53 mutations in various populations, and there is evidence supporting the fact that different exposures lead to specific p53 mutations types [28, 55, 56] . However, this evidence is limited in the case of breast cancer, and in our study, we did not see differences in mutation type according to exposure. Therefore, the possible relationship between adiposity, p53 mutation type, and p53 expression in breast cancer will need to be further investigated in larger sample size studies or metaanalyses on the data from the IARC database.
In evaluation of the findings from this study, it is important to understand its strengths and weaknesses. The main strength of this study is the detailed examination of p53 mutations in tumors from a large sample of breast cancer cases as well as the extensive questionnaire data and interviewer-administered measurements of anthropometry. In addition, because this is a population-based study, our study is representative of the broader population of breast cancer cases. The microarray assay that we used to measure p53 mutations is more robust compared to immunohistochemistry, and has similar or even superior performance in detecting point mutation compared to sequencing as previously showed by us and others [33, [57] [58] [59] .
Our study is not without limitations. Our relatively small sample size of pre-menopausal women and small number of women with certain types of p53 mutations (transversions) limited our ability to detect associations of p53 mutations and other characteristics in these groups. In spite of low power to detect associations in our pre-menopausal sample, the ORs were in similar direction to those of postmenopausal cases, with respect to women with the clinical characteristics of the tumors, indicating that the associations are likely similar. The associations were less similar with respect to adiposity; the trends with increasing waist circumference and waist-to-hip ratio were not linear nor statistically significant. These differences are consistent with the lack of a positive association of BMI and premenopausal breast cancer risk. However, these findings should be interpreted cautiously because of the limitations in sample size. Other limitations to the study include participation rates and the final analytic sample representing approximately 62 % of the entire sample of women who participated in the study. While 95 % of study participants with breast cancer gave consent for us to access their archived tumor specimen, we were unable to obtain tumor samples for a number of participants. As expected, we were less likely to obtain tissues for those with smaller tumors. Our sample from which we obtained tumor blocks also tended to be younger. These differences necessarily limit the generalizability of the study findings.
Clinical relevance comes into play with regard to identifying risk factors for heterogeneous breast cancer tumors, and identifying biologic pathways through which the risk factors influence breast cancer development. While obesity is not recognized as a risk factor for pre-menopausal breast cancer, our study suggests that adiposity is associated with unfavorable tumor characteristics, and thus, obesity prevention may be important for women who are at risk and also for women who have already developed aggressive breast cancer, since adiposity is considered to be a negative prognostic factor for breast cancer in both preand postmenopausal women. Our study can be validated in other case control studies that have measured p53 status and adiposity similarly using a case-only design; however, large studies are needed with larger representation of more aggressive tumor subtypes.
To our knowledge, this study is the first to identify an association of p53 status and adiposity in breast cancer. A causal relationship remains to be established. Replication of these findings would be important to better understand the mechanism of this association.
